Form 11-K
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 11-K

 


 

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Year Ended December 31, 2004

 

Commission File No. 000-04829

 


 

A. Full title of the plan and address of the plan, if different from that of the issuer named below:

 

Nabi Savings & Retirement Plan

 

B. Name of Issuer of the securities held pursuant to the plan and the address of its principal executive office:

 

Nabi Biopharmaceuticals

5800 Park of Commerce Blvd., NW

Boca Raton, FL 33487

(561) 989-5800

 



Table of Contents

NABI SAVINGS & RETIREMENT PLAN

 

Table of Contents

 

Report of Independent Registered Public Accounting Firm

   3

Financial Statements

    

Statements of Net Assets Available for Benefits

   4

Statement of Changes in Net Assets Available for Benefits

   4

Notes to Financial Statements

   5

Signature

   9

Supplemental Schedule

    

Schedule H, Line 4i - Schedule of Assets (Held at End of Year)

   10

Index to Exhibits

   11

 

2


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Participants and Administrator of the Nabi Savings & Retirement Plan

 

We have audited the accompanying statements of net assets available for benefits of the Nabi Savings & Retirement Plan as of December 31, 2004 and 2003, and the related statement of changes in net assets available for benefits for the year ended December 31, 2004. These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Plan’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2004 and 2003, and the changes in its net assets available for benefits for the year ended December 31, 2004, in conformity with U.S. generally accepted accounting principles.

 

Our audits were performed for the purpose of forming an opinion on the financial statements taken as a whole. The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2004, is presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. This supplemental schedule is the responsibility of the Plan’s management. The supplemental schedule has been subjected to the auditing procedures applied in our audits of the financial statements and, in our opinion, is fairly stated in all material respects in relation to the financial statements taken as a whole.

 

 

/s/ Ernst & Young LLP

Certified Public Accountants

 

 

West Palm Beach, Florida

June 17, 2005

 

3


Table of Contents

NABI SAVINGS & RETIREMENT PLAN

 

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

 

     December 31,

(In thousands)


   2004

   2003

Assets              

Investments, at fair value

   $ 20,055    $ 16,334

Receivables:

             

Contributions from employer

     1,382      1,091

Contributions from plan participants

     62      58
    

  

Net assets available for benefits

   $ 21,499    $ 17,483
    

  

 

See accompanying notes.

 

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

 

(In thousands)


   December 31,
2004


Additions:

      

Investment results:

      

Net appreciation in fair value of investments

   $ 1,637

Interest and dividend income

     449

Contributions:

      

From employer

     1,382

From plan participants

     2,524
    

Total additions

     5,992

Deductions:

      

Participant withdrawals

     1,899

Administrative expenses

     77
    

Total deductions

     1,976
    

Net increase

     4,016

Net assets available for benefits at beginning of year

     17,483
    

Net assets available for benefits at end of year

   $ 21,499
    

 

See accompanying notes.

 

4


Table of Contents

NABI SAVINGS & RETIREMENT PLAN

 

NOTES TO FINANCIAL STATEMENTS

 

1. Description of Plan

 

The following description of the Nabi Savings & Retirement Plan, or the Plan, provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions. Copies of this document are available from the Plan administrator.

 

General. The Plan is a defined contribution plan covering all eligible employees of Nabi Biopharmaceuticals. The Plan was adopted on April 1, 1985. Employees are eligible to participate in the Plan on the first day of the calendar quarter following the employee’s date of hire.

 

The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, or ERISA.

 

Contributions. Contributions to the Plan are made by employees, in the form of elective deferrals, and by Nabi Biopharmaceuticals. Each year, participants may elect to defer for contribution to the Plan up to 92% of their pre-tax annual compensation, limited by statutory maximum contributions, as defined by the Plan. Participants may also request that eligible rollover distributions from other qualified retirement plans be transferred into the Plan and credited to individual accounts maintained for their benefit. The amount contributed to the Plan annually is determined by the Nabi Biopharmaceuticals’ Board of Directors, in its discretion. With respect to the Plan year ending December 31,2004, Nabi Biopharmaceuticals contributed to the Plan a discretionary company matching contribution equal to 100% for an employee’s elective deferral contributions up to 4% of the participant’s earnings.

 

Investment Options. Upon enrollment in the Plan, a participant may direct the investment of the employee and employer contributions credited to his or her account into any of the Plan’s investment fund options. Participants may change their investment options on a daily basis. The Plan permits investment in Nabi Biopharmaceuticals common stock. The Plan implements participant directions to invest in Nabi Biopharmaceuticals common stock by purchasing the requested shares from the market.

 

Participant Accounts. Each participant’s account is credited with (a) the participant’s elective deferral contributions and rollover contributions, if any, (b) the participant’s share of employer contributions, (c) investment gains (or losses) attributable to (a) and (b); and each such account is charged with an allocation of administrative expenses. Employer contributions and administrative costs are allocated among accounts based on participants’ respective account balances or contributions, in accordance with formula set forth in the Plan. The benefit to which a participant is entitled is the benefit that can be provided by the participant’s vested account balance.

 

Vesting. Participants are 100% vested in their own contributions, current employer contributions and earnings thereon; however, certain employer contributions made for Plan years prior to 2002 were subject to vesting over time.

 

Participant Loans. Participants may borrow from their Plan accounts subject to a minimum of $1,000 and a maximum equal to the lesser of $50,000 or 50% of their vested account balances. Loan repayment

 

5


Table of Contents

periods are for a maximum of 5 years unless the loan is for the purchase of a primary residence, in which case a reasonable repayment period not to exceed 30 years is determined at the time of the loan. The loans are secured by a portion of the participant’s account balance equal to the amount of the loan and bear a reasonable rate of interest based on the local prevailing rate on the date approved. Principal and interest are paid ratably through payroll deduction.

 

Payment of Benefits. Upon death, disability, retirement, termination of service, or financial hardship, participants or their designated beneficiaries may receive a lump-sum distribution of their vested account balance (or, in the case of a financial hardship, that portion of their vested account balance attributable to their elective deferral contributions (excluding, without limitation, earnings thereon) and necessary to meet the hardship.

 

Forfeitures. The portion of account balances attributable to certain employer contributions made for Plan years prior to 2002 that was not vested when a participant terminated service with Nabi Biopharmaceuticals was subject to forfeiture. Forfeitures are held under the Plan for allocation and/or disposition in accordance with the terms of the Plan. Effective January 1, 2002, the Nabi-Rockville Savings & Retirement Plan merged with and into the Plan. Forfeitures under the Nabi-Rockville Savings & Retirement Plan in the amount of $12,000 were applied to reduce partially the employer contribution to the Plan relating to the 2002 Plan year.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation. The accompanying financial statements have been prepared on the accrual basis of accounting.

 

Valuation of Investments. The Plan’s investments are stated at fair value. The shares of registered investment companies are valued at quoted market prices that represent the net asset values of shares held by the Plan at year-end. Shares of Nabi Biopharmaceuticals common stock included in participant accounts are valued at quoted market price at year-end. Participant loans are valued at their outstanding balances, which approximate fair value.

 

Administrative Expenses. Fees and expenses of the Plan for legal, accounting and other administrative services may be paid out of Plan assets or, at Nabi Biopharmaceuticals’ discretion, directly by Nabi Biopharmaceuticals in whole or in part. During 2004, the Plan paid, with its assets, all administrative fees that it incurred.

 

Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.

 

6


Table of Contents

3. Investments

 

The fair values of individual investments that represent 5% or more of the Plan’s net assets at December 31, 2004 and 2003 are as follows:

 

(In thousands)


   2004

   2003

Smith Barney Corporate Trust Company:

             

Gabelli Growth Fund

   $ 3,790    $ 3,314

T. Rowe Price Equity Income Fund

     2,710      1,810

Janus Twenty Fund

     2,137      1,506

Nabi Biopharmaceuticals common stock

     1,876      1,389

Dreyfus Founders Discovery Fund

     1,861      1,576

Skyline Special Equities Fund

     1,778      1,582

Smith Barney Money Market - Government Portfolio

     1,638      1,420

Lazard International Equity Portfolio

     1,290      946

Strong Government Securities Fund

     *      1,023

* Investment not greater than 5%

 

The Plan’s investments, including investments bought, sold and held during the year, appreciated in fair value as follows:

 

(In thousands)


   December 31,
2004


Mutual funds

   $ 1,330

US government securities

     14

Common stocks

     293
    

     $ 1,637
    

 

4. Plan Termination

 

Although it has not expressed any intent to do so, Nabi Biopharmaceuticals has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA.

 

5. Income Tax Status

 

The Plan has received a determination letter from the Internal Revenue Service dated June 5, 2002, stating that the Plan is qualified under Section 401(a) of the Internal Revenue Code (the Code) and that the related trust is exempt from taxation. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan, as amended, is qualified under Code Section 401(a) and the related trust is tax-exempt under Code Section 501(a).

 

7


Table of Contents

6. Reconciliation of Financial Statements to Form 5500

 

The following is a reconciliation of net assets per the financial statements to the Form 5500 prepared for the Plan with respect to the Plan year ending December 31, 2004:

 

(In thousands)


   December 31,
2004


   December 31,
2003


 

Net assets available for benefits per the financial statements

   $ 21,499    $ 17,483  

Benefits approved but unpaid

     —        (15 )
    

  


Net assets available for benefits per the Form 5500

   $ 21,499    $ 17,468  
    

  


 

The following is a reconciliation of the benefits paid per the financial statements to the Form 5500 for the year ended December 31, 2004:

 

(In thousands)


   December 31,
2004


 

Participant withdrawals per the financial statements

   $ 1,899  

Benefit claim payable from December 31, 2003 Form 5500

     (15 )

Amounts allocated on Form 5500 to withdrawn participants at December 31, 2004

     —    
    


Benefits paid per the Form 5500

   $ 1,884  
    


 

Amounts allocated to participants who qualify for and have requested distributions (or are subject to mandatory distributions) from the Plan, e.g., based on separation from service, are recorded on the Form 5500 as benefits paid and include benefits that have been processed and approved for payment prior to year-end but not yet paid.

 

8


Table of Contents

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan administrator has duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    Nabi Savings & Retirement Plan
    By:   Nabi Biopharmaceuticals, Plan Administrator
Date: June 28, 2005   By:  

/s/ Mark L. Smith


        Mark L. Smith
       

Senior Vice President, Finance, Chief Financial Officer,

Chief Accounting Officer, and Treasurer

 

9


Table of Contents

Nabi Savings and Retirement Plan

 

EIN: 59-1212264 Plan No.: 001

Schedule H, Line 4i—

Schedule of Assets (Held at End of Year)

 

December 31, 2004

 

(a)


  

(b)

Identity of Issue, Borrower, Lessor, or

Similar Party


  

(c)

Description of Investment, Including

Maturity Date, Rate of Interest,

Collateral, Par, or Maturity Value


  

(d)


  

(e)

Current

Value


*    Smith Barney Corporate Trust    Gabelli Growth Fund         $ 3,789,585
          T. Rowe Price Equity Income Fund           2,709,915
          Janus Twenty Fund           2,136,722
          Dreyfus Founders Discovery Fund           1,861,237
          Skyline Special Equities Fund           1,778,029
          Smith Barney Money Market - Government Portfolio           1,638,199
          Lazard International Equity Portfolio           1,290,267
          Wells Adv Government Securities           922,096
          Credit Suisse Emerging Markets Fund           682,430
          Loomis Sayles Bond Fund           361,705
          ING GNMA Income Fund           339,814
          American Century International Bond           220,683
*    Nabi Biopharmaceuticals    Common Stock, par value $.10 per share           1,876,314
*    Participant Loans    Interest rates between 5.25% - 10.50%           447,968
                   

                    $ 20,054,964
                   


* Represents a party in interest

 

Note: Cost information has not been included in column (d) because all investments are participant-directed.

 

10


Table of Contents

INDEX TO EXHIBITS

 

Exhibits

      

Page

Number


23.1   Consent of Independent Registered Public Accounting Firm    12

 

11

Consent of Ernst & Young LLP

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-38868) pertaining to the Nabi Savings & Retirement Plan of our report dated June 17, 2005, with respect to the financial statements and schedule of the Nabi Savings & Retirement Plan included in this Annual Report (Form 11-K) for the year ended December 31, 2004.

 

 

 

                                                         /s/ Ernst & Young LLP

                                                         Certified Public Accountants

 

 

West Palm Beach, Florida

June 23, 2005

 

12